Advanced Oncotherapy (AVO) – Update on development milestones

Update on development milestones   Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, provides an update to shareholders on the continuing progress being made in the development of the Company’s novel proton accelerator, LIGHT, in the context of the milestones which were first set in November 2014 and […]

Proton beam therapy, the silver bullet for cancer? – Proactive Investors

by Josh Allsopp – Proactive Investors Radiotherapy remains the mainstay of cancer treatment, with over half of all patients undergoing radiation based treatment of some sort. There has been a great deal of coverage recently about the possibility of an ultimate cancer cure that uses the body’s own immune system to take out the killer […]

Daily Actions – UK Main & AIM market 14032016

Daily Actions is a daily summary analysis of changes in short term actions from our Daily Recs – AIM and Daily Recs Main markets reports. This report is typically distributed before the open of trading in London AIM Market ST Rec. changed From To Basic Resources     BMR Mining Neutral Buy Uranium Resources Neutral […]

British Medical Journal – A (relatively) risky business: the link between prostatic radiotherapy and second malignancies

This article published yesterday in the British Medical Journal and showing the link between radiotherapy and secondary tumour, highlights the need for a more targeted radiotherapy – i.e. Proton Beam Therapy There is a well recognized association between exposure to radiation and carcinogenesis. The development of second malignancies after therapeutic radiation depends on the primary […]

Advanced Oncotherapy (AVO) – Senior Management Appointments

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Michel Baelen has joined the Company as Head of Regulatory Affairs and Gerardo d’Auria has been appointed as a new Technical Director with immediate effect. Michel Baelen holds a Doctorate in management sciences from France and is graduated in Electrical […]

Advanced Oncotherapy (AVO) – Rocket Science – All Set for Take-off

A research note from Beaufort Securities. A small, young company with limited financial resources, trying to take on giant, established international peers with exceptionally deep pockets, in a product area that both tests the limits of scientific understanding whilst also facing the scrutiny of the world’s most exhaustive regulators? Sounds like a recipe for disaster! […]

Advanced Oncotherapy (AVO) – Recent article and Speculative Buy rating from Beaufort Securities

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, yesterday made two important announcements. One being the realignment of roles and responsibilities of the Executive team, the other being a prospectively far reaching industrialisation agreement with Thales, the giant and highly prestigious French multinational technology design and manufacturing group. 1) The agreement […]

Advanced Oncotherapy (AVO) – Holdings in Company

Aviva Plc and it’s subsidiaries announces a change in voting rights. From 83,873,902 shares directly owned, the group now has a direct interest of 56,693,779 shares (3.99%), an indirect interest of 25,998,794 shares (1.84%) and a right of recall to loaned shares of 1,163,720 (0.08%). Total number of voting rights are 83,856,293 shares (5.91%).